A 6-month-old girl born to consanguineous parents in Tamil Nadu presents with progressive loss of developmental milestones, seizures, and blindness. On examination, she has a cherry-red spot on the macula, hepatosplenomegaly, and developmental regression. Serum acid phosphatase is elevated. Genetic testing reveals mutations in the GM2AP (GM2 activator protein) gene. Which lysosomal storage disorder does this patient have, and what is the primary biochemical defect?

Explanation

## Clinical Diagnosis: GM2 Gangliosidosis Variant AB ### Key Diagnostic Features **Key Point:** GM2 gangliosidosis variant AB is a rare autosomal recessive lysosomal storage disorder caused by mutations in the GM2AP gene, which encodes the GM2 activator protein. This protein is essential for presenting GM2 ganglioside to hexosaminidase enzymes for degradation. ### Pathophysiology The GM2 activator protein (GM2AP) is a lipid-binding cofactor that: 1. Extracts GM2 ganglioside from lysosomal membranes 2. Presents it to hexosaminidase A (Hex-A) and hexosaminidase B (Hex-B) 3. Facilitates enzymatic cleavage of the terminal N-acetylgalactosamine residue **Without functional GM2AP:** - Hex-A and Hex-B enzyme levels are NORMAL - GM2 ganglioside accumulates in lysosomes (cannot be accessed by enzymes) - Neuronal and retinal cells are predominantly affected ### Clinical Presentation | Feature | Timing | Pathophysiology | | --- | --- | --- | | Developmental regression | 3–6 months | GM2 accumulation in neurons | | Seizures | 6–12 months | Neuronal dysfunction | | Blindness (cherry-red spot) | 6–12 months | GM2 in retinal ganglion cells | | Hepatosplenomegaly | 6–12 months | Macrophage infiltration | | Death | 2–4 years | Progressive neurodegeneration | ### Cherry-Red Spot: The Hallmark Sign **High-Yield:** A cherry-red spot on the macula is pathognomonic for GM2 gangliosidosis (Tay-Sachs, Sandhoff, and variant AB) and is caused by: - Accumulation of GM2 ganglioside in retinal ganglion cells surrounding the fovea - The fovea appears red (normal retina) against a white/pale surrounding retina (lipid-laden cells) - Results in blindness due to loss of central vision ### Differential Diagnosis: The Three Forms of GM2 Gangliosidosis | Feature | Tay-Sachs (Type I) | Sandhoff (Type II) | Variant AB | | --- | --- | --- | --- | | **Genetic defect** | HEXA gene (Hex-A subunit) | HEXB gene (Hex-B subunit) | GM2AP gene (activator protein) | | **Enzyme levels** | Hex-A ↓↓, Hex-B normal | Hex-A ↓, Hex-B ↓↓ | Hex-A normal, Hex-B normal | | **Substrate accumulation** | GM2 ganglioside | GM2 + globoside | GM2 ganglioside | | **Frequency** | Most common (~90% of GM2) | ~10% of GM2 | Rarest (~1% of GM2) | | **Ethnic predisposition** | Ashkenazi Jewish | Pan-ethnic | Pan-ethnic | | **Diagnostic test** | Hex-A deficiency on enzyme assay | Hex-B deficiency on enzyme assay | **Normal enzyme levels** + GM2AP mutation | | **Key distinguishing feature** | Hex-A deficiency | Hex-B deficiency | **Normal enzymes but absent activator protein** | ### Diagnostic Approach **Step 1: Clinical suspicion** - Cherry-red spot + developmental regression + hepatosplenomegaly → GM2 gangliosidosis **Step 2: Enzyme assay (leukocytes or fibroblasts)** - Tay-Sachs: Hex-A severely reduced; Hex-B normal - Sandhoff: Both Hex-A and Hex-B reduced - Variant AB: **Both Hex-A and Hex-B normal** ← KEY FINDING **Step 3: Genetic testing** - Variant AB confirmed by GM2AP gene mutations **Step 4: Substrate analysis** - Urine oligosaccharides show GM2 ganglioside accumulation **Clinical Pearl:** Variant AB is the diagnostic trap — enzyme assays appear normal, but the patient has a severe lysosomal storage disorder. Genetic testing is mandatory when clinical features suggest GM2 gangliosidosis but enzymes are normal. ### Management - **Supportive care:** Seizure management, nutritional support, physical/occupational therapy - **Substrate reduction therapy (experimental):** Miglustat (iminosugar) — slows progression but does not reverse neurodegeneration - **Gene therapy (investigational):** AAV-mediated GM2AP gene delivery - **Prognosis:** Progressive neurodegeneration; death typically by age 3–4 years **Mnemonic for GM2 gangliosidosis variants:** - **TAY-SACHS = Hex-A deficiency** (A comes first alphabetically) - **SANDHOFF = Hex-B deficiency** (B comes second) - **VARIANT AB = Activator protein deficiency** (AB = Activator Broken)